




Instance: composition-en-0cf0f03b0e4fcf8a0933d166c0dbe690
InstanceOf: CompositionUvEpi
Title: "Composition for vildagliptin Package Leaflet"
Description:  "Composition for vildagliptin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp555d0a7fb16f3bce450ed84172511640)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vildagliptin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Vildagliptin/Metformin hydrochloride Accord is and what it is used for </li>
<li>What you need to know before you take Vildagliptin/Metformin hydrochloride Accord  </li>
<li>How to take Vildagliptin/Metformin hydrochloride Accord  </li>
<li>Possible side effects </li>
<li>How to store Vildagliptin/Metformin hydrochloride Accord  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vildagliptin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vildagliptin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The active substances of Vildagliptin/Metformin hydrochloride Accord, vildagliptin and metformin 
hydrochloride, belong to a group of medicines called  oral antidiabetics . </p>
<p>Vildagliptin/Metformin hydrochloride Accord is used to treat adult patients with type 2 diabetes. This 
type of diabetes is also known as non-insulin dependent diabetes mellitus. Vildagliptin/Metformin 
hydrochloride Accord is used when diabetes cannot be controlled by diet and exercise alone and/or 
with other medicines used to treat diabetes (insulin or sulphonylureas). </p>
<p>Type 2 diabetes develops if the body does not make enough insulin or if the insulin that the body 
makes does not work as well as it should. It can also develop if the body produces too much glucagon. </p>
<p>Both insulin and glucagon are made in the pancreas. Insulin helps to lower the level of sugar in the 
blood, especially after meals. Glucagon triggers the liver to make sugar, causing the blood sugar level 
to rise. </p>
<p>How Vildagliptin/Metformin hydrochloride Accord works 
Both active substances, vildagliptin and metformin, help to control the level of sugar in the blood. The 
substance vildagliptin works by making the pancreas produce more insulin and less glucagon. The 
substance metformin works by helping the body to make better use of insulin. This medicine has been 
shown to reduce blood sugar, which may help to prevent complications from your diabetes. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vildagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vildagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Vildagliptin/Metformin hydrochloride Accord<br />
- if you are allergic to vildagliptin, metformin or any of the other ingredients of this medicine 
(listed in section 6). If you think you may be allergic to any of these, talk to your doctor before 
taking Vildagliptin/Metformin hydrochloride Accord. 
- if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood 
glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see  Risk of lactic 
acidosis  below) or ketoacidosis. Ketoacidosis is a condition in which substances called ketone 
bodies accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include 
stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual fruity 
smell. 
- if you have recently had a heart attack or if you have heart failure or serious problems with your 
blood circulation or difficulties in breathing which could be a sign of heart problems. 
- if you have severely reduced kidney function. 
- if you have a severe infection or are seriously dehydrated (have lost a lot of water from your 
body). 
- if you are going to have a contrast x-ray (a specific type of x-ray involving an injectable dye). 
Please also see information about this in section  Warnings and precautions . 
- if you have liver problems. 
- if you drink alcohol excessively (whether every day or only from time to time). 
- if you are breast-feeding (see also  Pregnancy and breast-feeding ). </p>
<p>Warnings and precautions </p>
<p>Risk of lactic acidosis 
Vildagliptin/Metformin hydrochloride Accord may cause a very rare, but very serious side effect 
called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing 
lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or 
alcohol intake, dehydration (see further information below), liver problems and any medical 
conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart 
disease). 
If any of the above apply to you, talk to your doctor for further instructions. </p>
<p>Stop taking Vildagliptin/Metformin hydrochloride Accord for a short time if you have a 
condition that may be associated with dehydration (significant loss of body fluids) such as severe 
vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor 
for further instructions. </p>
<p>Stop taking Vildagliptin/Metformin hydrochloride Accord and contact a doctor or the nearest 
hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition 
may lead to coma. 
Symptoms of lactic acidosis include:</p>
<ul>
<li>vomiting </li>
<li>stomach ache (abdominal pain) </li>
<li>muscle cramps </li>
<li>a general feeling of not being well with severe tiredness </li>
<li>difficulty in breathing </li>
<li>reduced body temperature and heartbeat </li>
</ul>
<p>Lactic acidosis is a medical emergency and must be treated in a hospital. </p>
<p>Vildagliptin/Metformin hydrochloride Accord is not a substitute for insulin. Therefore, you should not 
receive Vildagliptin/Metformin hydrochloride Accord for the treatment of type 1 diabetes. </p>
<p>Talk to your doctor, pharmacist or nurse before taking Vildagliptin/Metformin hydrochloride Accord<br />
if you have or have had a disease of the pancreas. </p>
<p>Talk to your doctor, pharmacist or nurse before taking Vildagliptin/Metformin hydrochloride Accord 
if you are taking an anti-diabetic medicine known as a sulphonylurea. Your doctor may want to reduce 
your dose of the sulphonylurea when you take it together with Vildagliptin/Metformin hydrochloride 
Accord  in order to avoid low blood glucose (hypoglycaemia). </p>
<p>If you have previously taken vildagliptin but had to stop taking it because of liver disease, you should 
not take this medicine. 
Diabetic skin lesions are a common complication of diabetes. You are advised to follow the 
recommendations for skin and foot care that you are given by your doctor or nurse. You are also 
advised to pay particular attention to new onset of blisters or ulcers while taking 
Vildagliptin/Metformin hydrochloride Accord. Should these occur, you should promptly consult 
your doctor. </p>
<p>If you need to have major surgery you must stop taking Vildagliptin/Metformin hydrochloride Accord <br />
during and for some time after the procedure. Your doctor will decide when you must stop and when 
to restart your treatment with Vildagliptin/Metformin hydrochloride Accord.. </p>
<p>A test to determine your liver function will be performed before the start of Vildagliptin/Metformin 
hydrochloride Accord  treatment, at three-month intervals for the first year and periodically thereafter. 
This is so that signs of increased liver enzymes can be detected as early as possible. </p>
<p>During treatment with Vildagliptin/Metformin hydrochloride Accord your doctor will check your 
kidney function at least once a year or more frequently if you are elderly and/or have worsening renal 
function. </p>
<p>Your doctor will test your blood and urine for sugar regularly. </p>
<p>Children and adolescents 
The use of Vildagliptin/Metformin hydrochloride Accord in children and adolescents up to 18 years of 
age is not recommended. </p>
<p>Other medicines and Vildagliptin/Metformin hydrochloride Accord 
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for 
example in the context of an X-ray or scan, you must stop taking Vildagliptin/Metformin 
hydrochloride Accord before or at the time of the injection. Your doctor will decide when you must 
stop and when to restart your treatment with Vildagliptin/Metformin hydrochloride Accord.. </p>
<p>Tell your doctor if you are taking, have recently taken or might take any other medicines. You may 
need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the 
dosage of Vildagliptin/Metformin hydrochloride Accord.It is especially important to mention the 
following:</p>
<ul>
<li>glucocorticoids generally used to treat inflammation </li>
<li>beta-2 agonists generally used to treat respiratory disorders </li>
<li>other medicines used to treat diabetes </li>
<li>medicines which increase urine production (diuretics) </li>
<li>medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as 
ibuprofen and celecoxib) </li>
<li>certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II 
receptor antagonists) </li>
<li>certain medicines affecting the thyroid </li>
<li>certain medicines affecting the nervous system </li>
<li>certain medicines used to treat angina (e.g. ranolazine) </li>
<li>certain medicines used to treat HIV infection (e.g. dolutegravir) </li>
<li>certain medicines used to treat a specific type of thyroid cancer (medullary thyroid cancer) (e.g. 
vandetanib) </li>
<li>certain medicines used to treat heartburn and peptic ulcers (e.g cimetidine) </li>
</ul>
<p>Vildagliptin/Metformin hydrochloride Accord with alcohol 
Avoid excessive alcohol intake while taking Vildagliptin/Metformin hydrochloride Accord since this 
may increase the risk of lactic acidosis (please see section  Warnings and precautions ). </p>
<p>Pregnancy and breast-feeding 
- If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor 
for advice before taking this medicine. Your doctor will discuss with you the potential risk of 
taking Vildagliptin/Metformin hydrochloride Accord during pregnancy. 
- Do not use Vildagliptin/Metformin hydrochloride Accord if you are pregnant or breast-feeding 
(see also  Do not take Vildagliptin/Metformin hydrochloride Accord  ). </p>
<p>Ask your doctor or pharmacist for advice before taking any medicine. </p>
<p>Driving and using machines 
If you feel dizzy while taking Vildagliptin/Metformin hydrochloride Accord, do not drive or use any 
tools or machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vildagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vildagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The amount of Vildagliptin/ Metformin hydrochloride Accord that people have to take varies 
depending on their condition. Your doctor will tell you exactly the dose of Vildagliptin/ Metformin 
hydrochloride Accord to take. </p>
<p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>The recommended dose is one film-coated tablet of either 50 mg/850 mg or 50 mg/1000 mg taken 
twice a day </p>
<p>If you have reduced kidney function, your doctor may prescribe a lower dose. Also if you are taking 
an anti-diabetic medicine known as a sulphonylurea your doctor may prescribe a lower dose. </p>
<p>Your doctor may prescribe this medicine alone or with certain other medicines that lower the level of 
sugar in your blood. </p>
<p>When and how to take Vildagliptin/Metformin hydrochloride Accord 
- Swallow the tablets whole with a glass of water, 
- Take one tablet in the morning and the other in the evening with or just after food. Taking the 
tablet just after food will lower the risk of an upset stomach. </p>
<p>Continue to follow any advice about diet that your doctor has given you. In particular, if you are 
following a diabetic weight control diet, continue with this while you are taking Vildagliptin/ 
Metformin hydrochloride Accord </p>
<p>If you take more Vildagliptin/ Metformin hydrochloride Accord than you should 
If you take too many Vildagliptin/Metformin hydrochloride Accord tablets, or if someone else takes 
your tablets, talk to a doctor or pharmacist immediately. Medical attention may be necessary. If 
you have to go to a doctor or hospital, take the pack and this leaflet with you. </p>
<p>If you forget to take Vildagliptin/ Metformin hydrochloride Accord 
If you forget to take a tablet, take it with your next meal unless you are due to take one then anyway. 
Do not take a double dose (two tablets at once) to make up for a forgotten tablet. </p>
<p>If you stop taking Vildagliptin/ Metformin hydrochloride Accord 
Continue to take this medicine as long as your doctor prescribes it so that it can continue to control 
your blood sugar. Do not stop taking Vildagliptin/Metformin hydrochloride Accord unless your doctor 
tells you to. If you have any questions about how long to take this medicine, talk to your doctor. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>You should stop taking Vildagliptin/Metformin hydrochloride Accord and see your doctor 
immediately if you experience the following side effects: </p>
<p>Lactic acidosis (very rare: may affect up to 1  n 10-000 people): 
Vildagliptin/Metformin hydrochloride Accord may cause a very rare, but very serious side 
effect called lactic acidosis (see section  Warnings and precautions ). If this happens you must 
stop taking Vildagliptin/Metformin hydrochloride Accord and contact a doctor or the 
nearest hospital immediately, as lactic acidosis may lead to coma. </p>
<p>Angioedema (rare: may affect up to 1 in 1,000 people): Symptoms include swollen face, tongue 
or throat, difficulty swallowing, difficulty breathing, sudden onset of rash or hives, which may 
indicate a reaction called  angioedema . </p>
<p>Liver disease (hepatitis) (uncommon: may affect up to 1 in 100 people): Symptoms include 
yellow skin and eyes, nausea, loss of appetite or dark-coloured urine, which may indicate liver 
disease (hepatitis). </p>
<p>Inflammation of the pancreas (pancreatitis) (uncommon: may affect up to 1 in 100 people): 
Symptoms include severe and persistent pain in the abdomen (stomach area), which might reach 
through to your back, as well as nausea and vomiting. </p>
<p>Other side effects 
Some patients have experienced the following side effects while taking Vildagliptin/metformin 
hydrochloride Accord: </p>
<p>Common (may affect up to 1 in 10 people): sore throat, runny nose, fever, itchy rash, excessive 
sweating, joint pain,  dizziness, headache, trembling that cannot be controlled, constipation, 
nausea (feeling sick), vomiting, diarrhoea, flatulence, heartburn, pain in and around the stomach 
(abdominal pain). </p>
<p>Uncommon (may affect up to 1 in 100 people):, tiredness, weakness, metallic taste, low blood 
glucose, loss of appetite, swollen hands, ankles or feet (oedema), chills, inflammation of the 
pancreas, muscle pain. </p>
<p>Very rare (may affect up to 1 in 10,000 people):; signs of a high level of lactic acid in the blood 
(known as lactic acidosis) such as drowsiness or dizziness, severe nausea or vomiting, 
abdominal pain, irregular heart beat or deep, rapid breathing; redness of the skin, itching; 
decreased vitamin B12 levels (paleness, tiredness, mental symptoms such as confusion or 
memory disturbances). </p>
<p>Since this product has been marketed, the following side effects have also been reported: </p>
<p>Frequency not known (cannot be estimated from the available data):, localised peeling of skin or 
blisters, blood vessel inflammation (vasculitis) which may result in skin rash or pointed, flat, 
red, round spots under the skin's surface or bruising.. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vildagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vildagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Keep this medicine out of the sight and reach of children. </li>
<li>Do not use this medicine after the expiry date which is stated on the blister and carton after 
 EXP .  </li>
<li>The expiry date refers to the last day of that month. </li>
<li>This does not require any special storage conditions. </li>
<li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist 
how to throw away medicines you no longer use. These measures will help protect the 
environment. </li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vildagliptin/ Metformin hydrochloride Accord contains 
- The active substances are vildagliptin and metformin hydrochloride. </p>
<p>Each Vildagliptin/ Metformin hydrochloride Accord 50 mg/850 mg film-coated tablet contains 
50 mg vildagliptin and 850 mg metformin hydrochloride (corresponding to 660 mg of 
metformin). </p>
<p>Each Vildagliptin/ Metformin hydrochloride Accord 50 mg/1000 mg film-coated tablet 
contains 50 mg vildagliptin and 1000 mg metformin hydrochloride (corresponding to mg of metformin). </p>
<ul>
<li>
<p>The other ingredients are:</p>
</li>
<li>
<p>Tablet core: Hydroxypropylcellulose, low-substitutehydroxypropylcellulose, microcrystalline 
cellulose, magnesium stearate </p>
</li>
<li>Film-coating: Hypromellose, titanium dioxide (E171), iron oxide yellow (E172), macrogol, talc </li>
</ul>
<p>What Vildagliptin/Metformin hydrochloride Accord contains looks like and contents of the pack 
Vildagliptin/ Metformin hydrochloride Accord 50mg/850mg film-coated tablets<br />
Yellow, oval shaped, biconvex, film coated tablet, debossed with "GG2" on one side and plain on 
other side. The size of the tablet is approximately 20.15 x 8.00 mm. </p>
<p>Vildagliptin/ Metformin hydrochloride Accord 50mg/1000mg film-coated tablets<br />
Dark yellow, oval shaped, biconvex, film coated tablet, debossed with "GG3" on one side and plain on 
other side. The size of the tablet is approximately 21.11 x 8.38 mm. </p>
<p>Vildagliptin/ Metformin hydrochloride Accord is available in aluminium/aluminium blisters of 30, or 180 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Accord Healthcare S.L.U 
World Trade Center, Moll de Barcelona s/n,<br />
Edifici Est, 6a planta, Barcelona, 
08039 Barcelona, Spain </p>
<p>Manufacturer 
LABORATORI FUNDACI  DAU 
C/ C, 12-14 Pol. Ind. Zona Franca, 
Barcelona, 08040, Spain </p>
<p>Pharmadox Healthcare Ltd. 
KW20A Kordin Industrial Park 
Paola, PLA 3Malta </p>
<p>Accord Healthcare Polska Sp. z o.o. 
Ul. Lutomierska 50,<br />
95-200 Pabianice, Poland </p>
<p>Accord Healthcare B.V. 
Winthontlaan 200,Utrecht,3526 KV, 
Netherlands </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-0cf0f03b0e4fcf8a0933d166c0dbe690
InstanceOf: CompositionUvEpi
Title: "Composition for vildagliptin Package Leaflet"
Description:  "Composition for vildagliptin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp555d0a7fb16f3bce450ed84172511640)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vildagliptin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Vildagliptin/Metformin hydrochloride Accord </li>
<li>Sådan skal du tage Vildagliptin/Metformin hydrochloride Accord </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vildagliptin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vildagliptin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>De aktive stoffer i Vildagliptin/Metformin hydrochloride Accord, vildagliptin og 
metforminhydrochlorid, tilhører en gruppe lægemidler, der kaldes "orale antidiabetika". </p>
<p>Vildagliptin/Metformin hydrochloride Accord bruges til at behandle voksne patienter med type 2-
diabetes (sukkersyge). Denne type diabetes kaldes også ikke-insulinkrævende diabetes mellitus. 
Vildagliptin/Metformin hydrochloride Accord bruges når diabetes ikke er tilstrækkeligt kontrolleret 
ved hjælp af kost og motion alene og/eller med andre lægemidler til behandling af diabetes (insulin 
eller sulfonylurinstoffer). </p>
<p>Du får type 2-diabetes, hvis kroppen ikke producerer insulin nok, eller hvis det insulin kroppen 
producerer, ikke fungerer så godt, som det skulle. Du kan også få det, hvis kroppen producerer for 
meget glucagon. </p>
<p>Både insulin og glucagon produceres i bugspytkirtlen. Insulin er med til at sænke blodsukkeret, især 
efter måltiderne. Glucagon får leveren til at producere sukker, hvilket får blodsukkeret til at stige. </p>
<p>Hvordan Vildagliptin/Metformin hydrochloride Accord virker 
De to aktive stoffer, vildagliptin og metformin, hjælper med at kontrollere blodsukkeret. Stoffet 
vildagliptin virker ved at få bugspytkirtlen til at producere mere insulin og mindre glucagon. Stoffet 
metformin virker ved at hjælpe kroppen til at udnytte insulinet bedre. Dette lægemiddel har vist sig at 
nedsætte blodsukkerniveauet, og dette kan medføre, at du undgår komplikationer, som opstår på grund 
af sukkersyge. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vildagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vildagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Vildagliptin/Metformin hydrochloride Accord 
- hvis du er allergisk over for vildagliptin, metformin eller et af de øvrige indholdsstoffer (angivet 
i punkt 6). Hvis du tror, at du måske er allergisk over for et eller flere af disse stoffer, så tal med 
din læge, før du begynder at tage Vildagliptin/Metformin hydrochloride Accord. 
- hvis du har dårligt kontrolleret diabetes, der eksempelvis er ledsaget af alvorlig hyperglykæmi 
(højt blodsukker), kvalme, opkastning, diarré, hurtigt vægttab, laktatacidose (se "Risiko for 
laktatacidose" nedenfor) eller ketoacidose. Ketoacidose er en tilstand, hvor såkaldte ketonstoffer 
ophobes i blodet, hvilket kan føre til diabetisk prækoma. Symptomerne omfatter mavesmerter, 
hurtig og dyb vejrtrækning og søvnighed, og din ånde kan få en usædvanlig frugtagtig lugt. 
- hvis du for nylig har haft et hjerteanfald, eller hvis du har haft hjertesvigt eller alvorlige 
problemer med blodcirkulationen eller åndedrætsbesvær, hvilket kan være tegn på 
hjerteproblemer. 
- hvis du har alvorligt nedsat nyrefunktion. 
- hvis du har en alvorlig infektion eller er alvorligt dehydreret (har mistet en masse vand fra 
kroppen). 
- hvis du skal have udført en røntgenundersøgelse med kontraststof (en speciel type røntgen, der 
involverer indsprøjtning af et farvestof). Se også information omkring dette i afsnittet 
"Advarsler og forsigtighedsregler". 
- hvis du har leverproblemer. 
- hvis du drikker for meget alkohol (uanset om det er hver dag eller kun engang imellem). 
- hvis du ammer (se også "Graviditet og amning"). </p>
<p>Advarsler og forsigtighedsregler </p>
<p>Risiko for laktatacidose 
Vildagliptin/Metformin hydrochloride Accord kan forårsage en meget sjælden, men meget alvorlig 
bivirkning, som kaldes laktatacidose, især hvis dine nyrer ikke fungerer korrekt. Risikoen for at 
udvikle laktatacidose er også forhøjet ved dårligt kontrolleret diabetes, alvorlige infektioner, 
længerevarende faste eller alkoholindtagelse, dehydrering (væskemangel (se yderligere oplysninger 
nedenfor)), leverproblemer og enhver tilstand med nedsat iltforsyning til en legemsdel (såsom akut 
alvorlig hjertesygdom). 
Kontakt lægen for at få yderligere vejledning, hvis noget af ovennævnte gælder for dig. </p>
<p>Stop med at tage Vildagliptin/Metformin hydrochloride Accord i en kort periode, hvis du har en 
tilstand, som kan være forbundet med dehydrering (betydeligt tab af kropsvæsker), såsom alvorlig 
opkastning, diarré, feber, udsættelse for varme eller indtagelse af mindre væske end normalt. Kontakt 
lægen for at få yderligere rådgivning. </p>
<p>Stop med at tage Vildagliptin/Metformin hydrochloride Accord og kontakt omgående læge eller 
nærmeste hospital, hvis du får et eller flere af nedenstående symptomer på laktatacidose, da 
denne tilstand kan føre til koma. 
Symptomerne på laktatacidose omfatter: </p>
<ul>
<li>
<p>opkastning </p>
</li>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>muskelkramper </p>
</li>
<li>
<p>almen utilpashed med udpræget træthed </p>
</li>
<li>
<p>vejrtrækningsbesvær </p>
</li>
<li>
<p>nedsat kropstemperatur og langsommere puls  </p>
</li>
</ul>
<p>Laktatacidose er en alvorlig tilstand, der skal behandles på et hospital. </p>
<p>Vildagliptin/Metformin hydrochloride Accord kan ikke erstatte insulin. Du bør derfor ikke få 
Vildagliptin/Metformin hydrochloride Accord til behandling af type 1-diabetes. </p>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Vildagliptin/Metformin 
hydrochloride Accord, hvis du har eller har haft en sygdom i bugspytkirtlen. </p>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Vildagliptin/Metformin 
hydrochloride Accord, hvis du tager lægemidler mod diabetes, kaldet sulfonylurinstof. For at undgå, at 
du får lavt blodsukker [hypoglykæmi], vil din læge måske nedsætte din dosis af sulfonylurinstoffet, 
når du tager det sammen med Vildagliptin/Metformin hydrochloride Accord. </p>
<p>Du må ikke tage dette lægemiddel igen, hvis du tidligere har taget vildagliptin, men blev nødt til at 
stoppe på grund af leversygdom. </p>
<p>Diabetiske hudlæsioner er en almindelig komplikation ved diabetes. Du bør følge de anbefalinger med 
hensyn til hud- og fodpleje, som du får af din læge eller sygeplejerske. Du bør også være særlig 
opmærksom på nye frembrud af blærer eller sår, mens du tager Vildagliptin/Metformin hydrochloride 
Accord. Skulle dette ske, skal du straks kontakte din læge. </p>
<p>Hvis du skal have en større operation, skal du stoppe med at tage Vildagliptin/Metformin 
hydrochloride Accord under indgrebet og i nogen tid herefter. Lægen vil beslutte, hvornår du skal 
stoppe behandlingen med Vildagliptin/Metformin hydrochloride Accord, og hvornår du kan genoptage 
den igen. </p>
<p>Du vil få taget en blodprøve til undersøgelse af din leverfunktion, før du starter med 
Vildagliptin/Metformin hydrochloride Accord-behandlingen, med tre måneders interval i det første år 
og derefter regelmæssigt. Dette gøres for at opdage tegn på forhøjede leverenzymer så hurtigt som 
muligt. </p>
<p>Under behandlingen med Vildagliptin/Metformin hydrochloride Accord vil lægen kontrollere din 
nyrefunktion mindst en gang om året eller hyppigere, hvis du er ældre, og/eller hvis din nyrefunktion 
bliver dårligere. </p>
<p>Lægen vil regelmæssigt teste dit blod og din urin for sukker. </p>
<p>Børn og unge 
Vildagliptin/Metformin hydrochloride Accord frarådes til børn og unge under 18 år. </p>
<p>Brug af andre lægemidler sammen med Vildagliptin/Metformin hydrochloride Accord 
Hvis du skal have sprøjtet et kontrastmiddel, som indeholder jod, ind i dit blod, for eksempel i 
forbindelse med en røntgenundersøgelse eller scanning, skal du stoppe med at tage 
Vildagliptin/Metformin hydrochloride Accord forud for eller på tidspunktet for injektionen. Lægen vil 
beslutte, hvornår du skal stoppe behandlingen med Vildagliptin/Metformin hydrochloride Accord, og 
hvornår du kan genoptage den igen. </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler. Du skal eventuelt have kontrolleret dit 
blodsukker eller din nyrefunktion hyppigere, eller lægen kan ændre din dosis af 
Vildagliptin/Metformin hydrochloride Accord. Det er især vigtigt, at du nævner følgende:</p>
<ul>
<li>lægemidler, der generelt bruges til behandling af betændelse (glukokortikoider) </li>
<li>lægemidler, der generelt bruges til behandling af åndedrætssygdomme (beta-2-agonister) </li>
<li>andre lægemidler, der bruges til at behandle diabetes </li>
<li>vanddrivende lægemidler (diuretika) </li>
<li>lægemidler mod smerter og betændelseslignende tilstande (NSAID’er og COX-2-hæmmere, 
såsom ibuprofen og celecoxib) </li>
<li>visse lægemidler, der nedsætter blodtrykket (ACE-hæmmere og angiotensin II-
receptorantagonister) </li>
<li>en bestemt type lægemidler, der påvirker skjoldbruskkirtlen </li>
<li>en bestemt type lægemidler, der påvirker nervesystemet </li>
<li>en bestemt type lægemidlertil behandling af hjertekrampe (angina) (fx ranolazin) </li>
<li>en bestemt type lægemidlertil behandling af HIV-infektion (fx dolutegravir) </li>
<li>en bestemt type lægemidlertil behandling af kræft i skjoldbruskkirtlen (medullær 
thyroideacancer) (fx vandetanib) </li>
<li>en bestemt type lægemidlertil behandling af halsbrand og mavesår (fx cimetidin) </li>
</ul>
<p>Brug af Vildagliptin/Metformin hydrochloride Accord sammen med alkohol 
Undgå at indtage store mængder alkohol, mens du tager Vildagliptin/Metformin hydrochloride 
Accord, da det kan øge risikoen for laktatacidose (se afsnittet "Advarsler og forsigtighedsregler"). </p>
<p>Graviditet og amning 
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du 
spørge din læge til råds, før du tager dette lægemiddel. Din læge vil tale med dig om de mulige 
risici ved at tage Vildagliptin/Metformin hydrochloride Accord under graviditet. 
Tag ikke Vildagliptin/Metformin hydrochloride Accord, hvis du er gravid eller ammer (se også 
"Tag ikke Vildagliptin/Metformin hydrochloride Accord"). </p>
<p>Spørg din læge eller apotekspersonalet til råds, før du bruger nogen form for lægemidler. </p>
<p>Trafik- og arbejdssikkerhed 
Hvis du føler dig svimmel, når du tager Vildagliptin/Metformin hydrochloride Accord, må du ikke 
føre motorkøretøj eller betjene værktøj og maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vildagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vildagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Det afhænger af din sygdom, hvor mange Vildagliptin/Metformin hydrochloride Accord-tabletter du 
skal tage. Din læge vil fortælle dig helt nøjagtigt, hvor mange Vildagliptin/ Metformin hydrochloride 
Accord du skal tage. </p>
<p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den anbefalede dosis er en filmovertrukken tablet på enten 50 mg/850 mg eller 50 mg/1000 mg 
2 gange daglig. </p>
<p>Din læge kan ordinere en lavere dosis, hvis du har nedsat nyrefunktion. Din læge kan også ordinere en 
lavere dosis, hvis du tager andre lægemidler (kaldet sulfonylurinstof) mod din diabetes. </p>
<p>Din læge kan ordinere dette lægemiddel alene eller sammen med visse andre lægemidler, som sænker 
blodsukkeret. </p>
<p>Hvornår og hvordan du skal tage Vildagliptin/Metformin hydrochloride Accord 
- Tabletterne synkes hele med et glas vand 
- Tag én tablet om morgenen og den anden om aftenen sammen med eller lige efter mad. Hvis du 
tager tabletten lige efter mad, vil det nedsætte risikoen for maveproblemer. </p>
<p>Fortsæt med at følge eventuelle kostråd, som din læge har givet dig. Især hvis du følger en 
diabetesdiæt med vægtkontrol, skal du fortsat følge denne, mens du tager Vildagliptin/Metformin 
hydrochloride Accord. </p>
<p>Hvis du har taget for meget Vildagliptin/Metformin hydrochloride Accord 
Du skal straks kontakte en læge eller apotekspersonalet, hvis du har taget for mange 
Vildagliptin/Metformin hydrochloride Accord-tabletter, eller hvis en anden tager dine tabletter. 
Lægebehandling kan være nødvendig. Tag pakningen og denne indlægsseddel med, hvis det er 
nødvendigt at gå til lægen eller på hospitalet. </p>
<p>Hvis du har glemt at tage Vildagliptin/Metformin hydrochloride Accord 
Hvis du glemmer at tage en tablet, skal du tage den sammen med det næste måltid, med mindre du 
alligevel skal tage en tablet på det pågældende tidspunkt. Du må ikke tage en dobbeltdosis (to tabletter 
på én gang) som erstatning for den glemte tablet. </p>
<p>Hvis du holder op med at tage Vildagliptin/Metformin hydrochloride Accord 
Bliv ved med at tage dette lægemiddel så længe din læge ordinerer det, så dit blodsukker vedbliver 
kontrolleret. Hold ikke op med at tage Vildagliptin/Metformin hydrochloride Accord, medmindre 
lægen siger det. Tal med din læge, hvis du har spørgsmål til, hvor længe du skal tage lægemidlet. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Du skal stoppe med at tage Vildagliptin/Metformin hydrochloride Accord og kontakte din læge 
omgående, hvis du oplever en eller flere af følgende bivirkninger: 
 
Laktatacidose (meget sjælden: kan forekomme hos op til 1 ud af 10.000 patienter): 
Vildagliptin/Metformin hydrochloride Accord kan forårsage en meget sjælden (kan forekomme 
hos op til 1 ud af 10.000 brugere), men meget alvorlig bivirkning, der kaldes laktatacidose (se 
afsnittet "Advarsler og forsigtighedsregler"). Hvis dette sker for dig, skal du omgående stoppe 
med at tage Vildagliptin/Metformin hydrochloride Accord og kontakte læge eller 
nærmeste hospital, da laktatacidose kan føre til koma. 
 
Angioødem (sjælden: kan forekomme hos op til 1 ud af 1.000 personer): symptomer inkluderer 
opsvulmet ansigt, tunge eller hals, problemer med at synke, problemer med at trække vejret, 
pludseligt udslæt eller nældefeber, der kan tyde på en reaktion, kaldet "angioødem". 
 
Leversygdom (hepatitis) (ikke almindelig: kan forekomme hos op til 1 ud af 100 patienter): 
symptomer inkluderer gul hud og øjne, kvalme, nedsat appetit eller mørk urin, hvilket kan tyde 
på en leversygdom (hepatitis). 
 
Betændelse i bugspytkirtlen (pankreatitis) (ikke almindelig: kan forekomme hos op til 1 ud af 
100 patienter): Symptomerne inkluderer stærke og vedvarende smerter i maven, der eventuelt 
breder sig til ryggen, samt kvalme og opkastning. </p>
<p>Andre bivirkninger 
Nogle patienter har oplevet følgende bivirkninger, mens de har taget Vildagliptin/Metformin 
hydrochloride Accord: 
 
Almindelige (kan forekomme hos op til 1 ud af 10 patienter): ondt i halsen, løbende næse, feber, 
kløende udslæt, kraftig svedtendens, ledsmerter, svimmelhed, hovedpine, rystelser der ikke kan 
styres, forstoppelse, kvalme, opkastning, diarré, luftafgang fra tarmen, sure opstød, smerter i og 
omkring maven. 
 
Ikke almindelige (kan forekomme hos op til 1 ud af 100 patienter): træthed, svaghed, 
metalsmag, lavt blodsukker, appetitløshed, hævede hænder, ankler eller fødder (ødem), 
kulderystelser, betændelse i bugspytkirtlen (pankreatitis), muskelsmerter. 
 
Meget sjældne (kan forekomme hos op til 1 ud af 10.000 patienter): tegn på et højt niveau af 
mælkesyre i blodet (kaldes laktatacidose), som fx sløvhed eller svimmelhed, alvorlig kvalme 
eller opkastning, mavesmerter, uregelmæssig hjerterytme eller dyb, hurtig vejrtrækning; rødme i 
huden, kløe; nedsat niveau af B12-vitamin (bleghed, træthed, mentale symptomer såsom 
forvirring eller problemer med hukommelsen). </p>
<p>Siden dette lægemiddel er blevet markedsført er følgende bivirkninger blevet rapporteret: 
 
Hyppighed ikke kendt (kan ikke estimeres ud fra forhåndenværende data): områder med 
afskalning af huden eller blærer i huden, betændelse i blodkar (vaskulitis), som kan medføre 
hududslæt eller tilspidsede, flade, røde, runde pletter under hudens overflade. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vildagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vildagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. 
Brug ikke lægemidlet efter den udløbsdato, der står på blisterkortet og æsken efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. 
Lægemidlet kræver ingen særlige opbevaringsforhold. 
Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vildagliptin/Metformin hydrochloride Accord indeholder:</p>
<ul>
<li>
<p>Aktive stoffer er vildagliptin og metforminhydrochlorid 
 Hver Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg filmovertrukken tablet 
indeholder 50 mg vildagliptin og 850 mg metforminhydrochlorid (svarende til 660 mg 
metformin). 
 Hver Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg filmovertrukken tablet 
indeholder 50 mg vildagliptin og 1000 mg metforminhydrochlorid (svarende til 780 mg 
metformin). </p>
</li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>Tabletkerne: Hydroxypropylcellulose, lavsubstitueret hydroxypropylcellulose, 
mikrokrystallinsk cellulose, magnesiumstearat </p>
</li>
<li>Filmovertræk: Hypromellose, titandioxid (E171), gul jernoxid (E172), macrogol, talcum </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg filmovertrukne tabletter 
Gule, ovale, bikonvekse filmovertrukne tabletter, præget med "GG2" på den ene side og glatte på den 
anden side. Tabletten måler ca. 20,158,00 mm. </p>
<p>Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg filmovertrukne tabletter 
Mørkegule, ovale, bikonvekse filmovertrukne tabletter, præget med "GG3" på den ene side og glatte 
på den anden side. Tabletten måler ca. 21,118,38 mm. </p>
<p>Vildagliptin/Metformin hydrochloride Accord fås i aluminium/aluminium-blisterstrips med 30, eller 180 filmovertrukne tabletter.  </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Accord Healthcare S.L.U 
World Trade Center, Moll de Barcelona s/n,<br />
Edifici Est, 6a planta, 
08039 Barcelona, Spanien </p>
<p>Fremstiller 
LABORATORI FUNDACIÓ DAU 
C/ C, 12-14 Pol. Ind. Zona Franca, 
Barcelona, 08040, Spanien </p>
<p>Pharmadox Healthcare Ltd. 
KW20A Kordin Industrial Park 
Paola, PLA 3Malta </p>
<p>Accord Healthcare Polska Sp. z o.o. 
Ul. Lutomierska 50,<br />
95-200 Pabianice, Polen </p>
<p>Accord Healthcare B.V. 
Winthontlaan 200, Utrecht,3526 KV, 
Holland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-0cf0f03b0e4fcf8a0933d166c0dbe690
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vildagliptin Package Leaflet for language en"
Description: "ePI document Bundle for vildagliptin Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-0cf0f03b0e4fcf8a0933d166c0dbe690"
* entry[0].resource = composition-en-0cf0f03b0e4fcf8a0933d166c0dbe690

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0cf0f03b0e4fcf8a0933d166c0dbe690"
* entry[=].resource = mp0cf0f03b0e4fcf8a0933d166c0dbe690
                            
                    
Instance: bundlepackageleaflet-da-0cf0f03b0e4fcf8a0933d166c0dbe690
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vildagliptin Package Leaflet for language da"
Description: "ePI document Bundle for vildagliptin Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-0cf0f03b0e4fcf8a0933d166c0dbe690"
* entry[0].resource = composition-da-0cf0f03b0e4fcf8a0933d166c0dbe690

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0cf0f03b0e4fcf8a0933d166c0dbe690"
* entry[=].resource = mp0cf0f03b0e4fcf8a0933d166c0dbe690
                            
                    



Instance: mp0cf0f03b0e4fcf8a0933d166c0dbe690
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product vildagliptin"
Description: "vildagliptin"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1611/001-006"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Vildagliptin/Metformin hydrochloride Accord  is indicated as an adjunct to diet and exercise to"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "vildagliptin"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 0cf0f03b0e4fcf8a0933d166c0dbe690ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vildagliptin"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vildagliptin"

* subject = Reference(mp555d0a7fb16f3bce450ed84172511640)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vildagliptin "vildagliptin"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-0cf0f03b0e4fcf8a0933d166c0dbe690) // vildagliptin en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-0cf0f03b0e4fcf8a0933d166c0dbe690) // vildagliptin da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-0cf0f03b0e4fcf8a0933d166c0dbe690
InstanceOf: List

* insert 0cf0f03b0e4fcf8a0933d166c0dbe690ListRuleset
    